SRC and neoplasm: Apatinib can effectively inhibit the kinase activity of VEGFR-2, c-kit and c-src, and inhibit the phosphorylation of VEGFR-2, c-kit and PDGFRβ to inhibit tumor growth, reduce microvessel density and promote tumor cell apoptosis in mice.